<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453853</url>
  </required_header>
  <id_info>
    <org_study_id>AFRICA</org_study_id>
    <nct_id>NCT03453853</nct_id>
  </id_info>
  <brief_title>Atrial Functional Mitral Regurgitation Response In Mitral Loop Cerclage Annuloplasty (AFRICA Study)</brief_title>
  <acronym>AFRICA</acronym>
  <official_title>The Study for Atrial Functional Mitral Regurgitation Response In Mitral Loop Cerclage Annuloplasty (AFRICA Study): Multi-center, Open Label, Single Arm, Feasibility Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tau Pnu Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tau Pnu Medical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate second stage safety and feasibility of Mitral Loop Cerclage(MLC) Annuloplasty&#xD;
      with CSTV for repair of functional mitral regurgitation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this prospective, single-center, open label, feasibility test is to assess&#xD;
      the safety and efficacy of Mitral Loop Cerclage Annuloplasty with CSTV protective device, in&#xD;
      treating functional mitral regurgitation (FMR) associated with heart failure and Atrial&#xD;
      Fibrillation mitral regurgitation Response in Mitral Loop Cerclage annuloplasty.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Actual">April 3, 2021</completion_date>
  <primary_completion_date type="Actual">November 17, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mitral regurgitation severity(1)</measure>
    <time_frame>1 month</time_frame>
    <description>changing regurgitant volume (RV,mL) compared with baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of mitral regurgitation severity(2)</measure>
    <time_frame>1 month</time_frame>
    <description>changing effective regurgitant orifice (ERO,cm^2) compared with baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mitral annulus geometry</measure>
    <time_frame>1 month</time_frame>
    <description>septal lateral dimension(mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse events as a measure of safety</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of composite endpoint of MACE (Major Adverse Cardiac Event) *death, myocardial infarction, cardiac tamponade, device related cardiac surgery, stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of mitral regurgitation severity(1)</measure>
    <time_frame>6 months</time_frame>
    <description>changing regurgitant volume (RV,mL) compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of mitral regurgitation severity(2)</measure>
    <time_frame>6 months</time_frame>
    <description>changing effective regurgitant orifice (ERO,cm^2) compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mitral annulus geometry</measure>
    <time_frame>6 months</time_frame>
    <description>septal lateral dimension(mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricle volumes</measure>
    <time_frame>6 months</time_frame>
    <description>Changing of End-diastolic phase LV volumes(mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical remodeling</measure>
    <time_frame>6 months</time_frame>
    <description>change in electrocardiography (conversion of atrial fibrillation to normal sinus rhythm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjects' symptoms referred to NYHA Classification System</measure>
    <time_frame>6 months</time_frame>
    <description>NYHA (New York Heart Association)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rate of the implantation</measure>
    <time_frame>6 months</time_frame>
    <description>Technical feasibility by the implantation success rate (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events as a measure of safety</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of composite endpoint of MACE (Major Adverse Cardiac Event) *death, myocardial infarction, cardiac tamponade, device related cardiac surgery, stroke</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Atrial Functional Mitral Regurgitation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Mitral Loop Cerclage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral Loop Cerclage Annuloplasty</intervention_name>
    <description>Atrial Functional mitral regurgitation Response In mitral loop Cerclage Annuloplasty</description>
    <arm_group_label>Mitral Loop Cerclage</arm_group_label>
    <other_name>(MLC-B-45-75-R and other 11 models)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NYHA(New York Heart Association) Class III - IV&#xD;
&#xD;
          -  and, Functional Mitral Regurgitation 3+ (Moderate/Severe) or 4+ (Severe) in spite of&#xD;
             optimal medical treatment.&#xD;
&#xD;
        (For optimal medical treatments, ①ACE inhibitor or angiotensin receptor blocker ②β-blocker&#xD;
        ③ aldosterone antagonists should be given for at least 3 months unless the subject has&#xD;
        contraindication for each drug)&#xD;
&#xD;
          -  and, Chronic Atrial Fibrillation in electrocardiography (Persistent AF or Permanent&#xD;
             AF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary Mitral Regurgitation&#xD;
&#xD;
          -  LV ejection fraction lower than 30%&#xD;
&#xD;
          -  Pulmonary arterial pressure ≥ 60mmHg&#xD;
&#xD;
          -  End-diastolic Left ventricular dimension ≥ 70mm&#xD;
&#xD;
          -  Subjects with functional MR who need CABG or AVR performed&#xD;
&#xD;
          -  Pre-existing stent in a coronary artery that is deemed to be in direct contact with&#xD;
             the path of mitral loop cerclage along coronary sinus&#xD;
&#xD;
          -  Subjects who have functional MR caused by aortic valve disease&#xD;
&#xD;
          -  Subjects who have uncontrollable hyperthyroidism&#xD;
&#xD;
          -  Subjects who have severe TR due to primary valve leaflet disease&#xD;
&#xD;
          -  Anomaly of Coronary Sinus&#xD;
&#xD;
          -  Pre-existing devices in coronary sinus such as Implantable Cardioverter Defibrillator&#xD;
             and Pacemaker&#xD;
&#xD;
          -  2:1 Atriventricular AV block or higher AV block and ventricular tachycardia&#xD;
&#xD;
          -  Subjects with primary MR&#xD;
&#xD;
          -  Subjects who cannot be screened by cardiac CT&#xD;
&#xD;
          -  Subjects who have possibility of coronary artery pinching even with Mitral Loop&#xD;
             Cerclage system judged by cardiac CT&#xD;
&#xD;
          -  Subjects who do not have septal vein or have unsuitable septal vein anatomy by cardiac&#xD;
             CT or venogram&#xD;
&#xD;
          -  Subjects who have thrombosis and embolism&#xD;
&#xD;
          -  Creatinine ≥2.0 mg/dL&#xD;
&#xD;
          -  Subjects who have coagulation disorders&#xD;
&#xD;
          -  Subjects who are unable to take anti-platelet agents&#xD;
&#xD;
          -  Pre-existing devices such as Implantable Cardioverter Defibrillator and Pacemaker&#xD;
&#xD;
          -  Subjects who are pregnant, or lactating, or plan pregnancy during the clinical trials&#xD;
&#xD;
          -  Subjects who are participated in other clinical trials within 1 month of enrollment&#xD;
&#xD;
          -  Subjects who are deemed not to be eligible in this study by physician's discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Hyun Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Dalseo-gu</state>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sejong HOSPITAL</name>
      <address>
        <city>Bucheon-si</city>
        <state>Gyeonggi-do</state>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnamdo</state>
        <zip>50602</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital (CNU Hospital)</name>
      <address>
        <city>Daejeon</city>
        <state>Jung-gu</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Nam-gu</state>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan Hospital</name>
      <address>
        <city>Ulsan</city>
        <state>Nam-gu</state>
        <zip>44686</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://content.onlinejacc.org/article.aspx?articleid=1139949</url>
    <description>Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: Initial results in swine</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S1936879817301498?via%3Dihub</url>
    <description>Mitral Loop Cerclage Annuloplasty for Secondary Mitral Regurgitation: First Human Results</description>
  </link>
  <reference>
    <citation>Kim JH, Kocaturk O, Ozturk C, Faranesh AZ, Sonmez M, Sampath S, Saikus CE, Kim AH, Raman VK, Derbyshire JA, Schenke WH, Wright VJ, Berry C, McVeigh ER, Lederman RJ. Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: initial results in swine. J Am Coll Cardiol. 2009 Aug 11;54(7):638-51. doi: 10.1016/j.jacc.2009.03.071.</citation>
    <PMID>19660696</PMID>
  </reference>
  <reference>
    <citation>Park YH, Chon MK, Lederman RJ, Sung SC, Je HG, Choo KS, Lee SH, Shin ES, Kim JS, Hwang KW, Lee SY, Chun KJ, Kim CM, Kim JH. Mitral Loop Cerclage Annuloplasty for Secondary Mitral Regurgitation: First Human Results. JACC Cardiovasc Interv. 2017 Mar 27;10(6):597-610. doi: 10.1016/j.jcin.2016.12.282.</citation>
    <PMID>28335897</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>Yong-Hyun Park,MD,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Percutaneous mitral valve repair</keyword>
  <keyword>Coronary sinus annuloplasty</keyword>
  <keyword>Mitral loop cerclage</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

